Demonstration of an anti-oxidative stress mechanism of quetiapine: implications for the treatment of Alzheimer's disease. (Q33343685)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18554300%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

title

Demonstration of an anti-oxidative stress mechanism of quetiapine: implications for the treatment of Alzheimer's disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18554300%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

0 references

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18554300%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Jiming Kong

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18554300%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

author name string

Haiyun Xu

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18554300%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Haitao Wang

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18554300%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Lixia Zhuang

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18554300%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Bin Yan

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18554300%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Yingxin Yu

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18554300%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Zelan Wei

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18554300%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Lillian E Dyck

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18554300%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Steven J Richardson

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18554300%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Jue He

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18554300%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Xiaokun Li

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18554300%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Xin-Min Li

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18554300%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

language of work or name

English

0 references

publication date

1 July 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18554300%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18554300%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

volume

275

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18554300%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

issue

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18554300%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

page(s)

3718-3728

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18554300%20AND%20SRC:MED&resulttype=core&format=json

Quetiapine. A review of its use in the management of schizophrenia

9 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

Effects of quetiapine on cognitive functions in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

Quetiapine treatment for behavioral and psychological symptoms in patients with senile dementia of Alzheimer type

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

Efficacy and tolerability of quetiapine in the treatment of behavioral and psychological symptoms of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

Quetiapine improves psychotic symptoms and cognition in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

Protective effects of atypical antipsychotic drugs on PC12 cells after serum withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

The ability of atypical antipsychotic drugs vs. haloperidol to protect PC12 cells against MPP+‐induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

Atypical antipsychotics attenuate neurotoxicity of beta-amyloid(25-35) by modulating Bax and Bcl-X(l/s) expression and localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

Olanzapine and quetiapine protect PC12 cells from beta-amyloid peptide(25-35)-induced oxidative stress and the ensuing apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

Different mechanisms of oxidative stress and neurotoxicity for Alzheimer's A beta(1--42) and A beta(25--35).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

Amyloid beta-protein toxicity and oxidative stress in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

A spectroscopic study of some of the peptidyl radicals formed following hydroxyl radical attack on beta-amyloid and alpha-synuclein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

Hydrogen peroxide mediates amyloid beta protein toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

Free radicals in the neurotoxic actions of beta-amyloid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

APP and PS-1 mutations induce brain oxidative stress independent of dietary cholesterol: implications for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

Alzheimer's disease and oxidative stress: implications for novel therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

The effect of serum withdrawal on the protein profile of quiescent human dermal fibroblasts in primary cell culture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

Rosiglitazone protects human neuroblastoma SH-SY5Y cells against MPP+ induced cytotoxicity via inhibition of mitochondrial dysfunction and ROS production

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

Oxidative stress potentiates BACE1 gene expression and Abeta generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

Role of oxidative stress and antioxidants in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

Mitochondrial complex I subunits expression is altered in schizophrenia: a postmortem study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

Possible involvement of free radicals in neuroleptic-induced movement disorders. Evidence from treatment of tardive dyskinesia with vitamin E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

Depletion of glutathione and enhanced lipid peroxidation in the CSF of acute psychotics following haloperidol administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

Atypical antipsychotic drugs and tardive dyskinesia: relevance of D2 receptor affinity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

Amisulpride-induced tardive dyskinesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

Cognitive and behavioral effects of quetiapine in Alzheimer disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

Interaction between synthetic amyloid-beta-peptide (1-40) and its aggregation inhibitors studied by electrospray ionization mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X

Oxidative Stress During Treatment With First- and Second-Generation Antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06519.X